Intracranial Pressure (ICP) Monitoring Devices Global Market Report 2024

The intracranial pressure (icp) monitoring devices market size has grown strongly in recent years. It will grow from $1.57 billion in 2023 to $1.68 billion in 2024 at a compound annual growth rate (CAGR) of 7.2%. The growth observed in the historical period can be attributed to several factors, including the increasing incidence of traumatic brain injuries (TBIs), a growing aging population, heightened awareness and diagnosis of relevant medical conditions, the phenomenon of medical tourism, the rise in the geriatric population, and the global improvement in healthcare awareness and accessibility.

The intracranial pressure (icp) monitoring devices market size is expected to see strong growth in the next few years. It will grow to $2.16 billion in 2028 at a compound annual growth rate (CAGR) of 6.4%. The anticipated growth in the forecast period can be attributed to various factors, including the adoption of personalized medicine approaches, the expansion of telemedicine and remote monitoring capabilities, an increase in the prevalence of chronic neurological disorders, integration with electronic health records (EHR), a global upsurge in neurosurgical procedures, and a heightened focus on outpatient monitoring. Prominent trends expected in the forecast period encompass the integration of artificial intelligence (AI), the development of continuous monitoring solutions, increased collaborations and partnerships, a focus on non-invasive monitoring techniques, and the emphasis on home-based intracranial pressure (ICP) monitoring.

The anticipated growth of the intracranial pressure (ICP) monitoring devices market is driven by the increasing incidence of traumatic brain injury (TBI). Traumatic brain injury involves damage to the brain caused by external forces or trauma, and its rising prevalence is primarily attributed to an uptick in motor vehicle accidents, sports injuries, and physical assaults. Intracranial pressure (ICP) monitoring devices play a crucial role in managing TBI cases by providing real-time information on skull pressure. Notably, the Brain Injury Association of America (BIAA) estimated in March 2021 that approximately 2.8 million people in the U.S. experience TBI annually, with around 280,000 requiring hospitalization. The staggering statistics reveal a TBI occurrence every nine seconds in the U.S., resulting in over 3.5 million injuries annually and approximately 50,000 fatalities. The escalating number of TBI cases is poised to drive the growth of the intracranial pressure (ICP) monitoring devices market.

The growth of the intracranial pressure (ICP) monitoring device market is expected to be fueled by the increasing prevalence of neurological diseases. Neurological diseases, encompassing a wide range of medical conditions affecting the nervous system, rely on intracranial pressure (ICP) monitoring devices for crucial insights into skull pressure management. The World Health Organization (WHO) reported in February 2023 that epilepsy, a neurological disorder, impacts 5 million individuals globally, with varying incidence rates in high-income and low- to middle-income countries. The rise in neurological diseases is a significant factor contributing to the growth of the intracranial pressure (ICP) monitoring device market.

Major companies in the market are actively seeking partnerships to fortify their market positions. For example, in November 2022, Sweden-based medical technology company IRRAS partnered with U.S.-based medical device company Medtronic, granting Medtronic exclusive rights to promote the IRRAflow system in specific U.S. territories. Another partnership in November 2022 involved U.S.-based EMOTIV collaborating with Israel-based X-trodes to launch a medical-grade, at-home solution for brain monitoring research, leveraging EMOTIV's expertise in electroencephalography (EEG) and X-trodes' wireless medical-grade monitoring solutions.

Major players in the intracranial pressure (ICP) monitoring device market are dedicating their efforts to developing cutting-edge therapies and treatments, exemplified by innovations such as the high-dose cohort of CTI-1601 and the SOMNUM AI device, aimed at elevating patient outcomes. The high-dose cohort of CTI-1601 represents a promising treatment for Friedreich's ataxia, a rare genetic disease. In a notable development, Larimar Therapeutics Inc., a biotechnology company based in the United States, obtained approval for the high-dose cohort of CTI-1601 in October 2023. Additionally, the SOMNUM AI device, designed for intracranial pressure monitoring and traumatic brain injury (TBI), received approval from the U.S. Food and Drug Administration (FDA). This strategic focus on innovative therapies reflects a commitment to advancing patient care in the intracranial pressure monitoring device market.

In January 2023, Natus Medical Incorporated, a prominent medical device company headquartered in the United States, successfully completed the acquisition of Micromed Holding SAS for an undisclosed amount. The primary objective behind this acquisition was to enhance Natus Medical's capabilities in the neurophysiology market, encompassing the diagnosis and monitoring of various neurological disorders and conditions. The collaboration between Natus Medical's existing product portfolio and Micromed's offerings presents opportunities for enhanced integration, innovation, and customer support within the neurophysiology market. Notably, Micromed Holding SAS is a U.S.-based provider of neurophysiology solutions and operates within the intracranial pressure (ICP) monitoring devices market.


Major companies operating in the intracranial pressure (icp) monitoring devices market report are Medtronic PLC, Integra LifeSciences Holding Corporation, Natus Medical Inc., Haiying Medical, Raumedic AG, Sophysa Ltd., Ad-Tech Medical Instrument Corp., Third Eye Diagnostics, Boston Neurosciences Inc., DePuy Synthes, Codman & Shurtleff Inc., NeuroWave Systems Inc., Branchpoint Technologies Inc., Cerebrotech Medical Systems Inc., Deltex Medical Group PLC, Gaeltec Devices Ltd., Infrascan Inc., NeuroDx Development, NeuroVent Research Inc., Noninvasix, Vivonics Inc., Neural Analytics, Spiegelberg GmbH and Co. KG, HeadSense Medical Ltd., Moberg ICU Solutions, Nisonic AS, Vittamed Corporation, Cerebral Assessment Systems Inc., Orsan Medical Technologies Ltd.

North America was the largest region in the intracranial pressure (ICP) monitoring devices market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intracranial pressure (icp) monitoring devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the intracranial pressure (icp) monitoring devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary techniques employed in intracranial pressure (ICP) monitoring devices include both invasive and non-invasive approaches. Invasive techniques involve the use of monitoring devices or methods that necessitate the insertion of a probe or sensor directly into the intracranial space or a specific location within the brain. These techniques find application in various medical scenarios such as traumatic brain injury, intracerebral hemorrhage, meningitis, subarachnoid hemorrhage, cerebrospinal fluid (CSF) management, migraine, stroke, hydrocephalus, electroencephalogram (EEG), and others. These devices are utilized by hospitals, ambulatory care facilities, clinics, and various other end-users.

The intracranial pressure (ICP) monitoring devices market research report is one of a series of new reports that provides intracranial pressure (ICP) monitoring devices market statistics, including intracranial pressure (ICP) monitoring devices industry global market size, regional shares, competitors with an intracranial pressure (ICP) monitoring devices market share, detailed intracranial pressure (ICP) monitoring devices market segments, market trends and opportunities, and any further data you may need to thrive in the intracranial pressure (ICP) monitoring devices industry. This intracranial pressure (ICP) monitoring devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The intracranial pressure (ICP) monitoring devices market consists of sales of intraparenchymal monitors, subdural monitors, epidural monitors, and ventricular catheters. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.